Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 9/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171362 | 0.81 | DRD2 (0.44) | IKBKB | |
| SCHEMBL30174508 | 0.74 | MEN1 (0.54) | MEN1KMT2AHRH4SLC18A3SIGMAR1 | |
| SCHEMBL12093290 | 0.74 | HTR2C (0.47) | MEN1KMT2AHRH4SLC18A3SIGMAR1 | |
| SCHEMBL30469416 | 0.74 | HTR2C (0.47) | MEN1KMT2AHRH4SLC18A3SIGMAR1 | |
| SCHEMBL24265537 | 0.74 | USP7 (0.45) | MEN1KMT2AHRH4SLC18A3SIGMAR1 | |
| SCHEMBL24338764 | 0.74 | MEN1 (0.54) | MEN1KMT2AHRH4SLC18A3SIGMAR1 | |
| SCHEMBL29554902 | 0.74 | USP7 (0.45) | MEN1KMT2AHRH4SLC18A3SIGMAR1 | |
| SCHEMBL171452 | 0.74 | HRH4 (0.50) | MEN1KMT2AHRH4SLC18A3SIGMAR1 | |
| SCHEMBL12975520 | 0.74 | MEN1 (0.42) | MEN1KMT2AHRH4SLC18A3SIGMAR1 | |
| SCHEMBL26482538 | 0.74 | MEN1 (0.42) | MEN1KMT2AHRH4SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530662-B2 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530662-B2 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2013-09-10 | — | — | US | disclosed |
| EP-2426120-A1 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | Fujifilm Finechemicals Co., Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | FUJIFILM FINECHEMICALS CO., LTD | 2010-02-04 | — | — | US | disclosed |
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | FUJIFILM FINECHEMICALS CO., LTD | 2010-02-04 | — | — | US | disclosed |
| US-7632950-B2 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2009-12-15 | — | — | US | disclosed |
| US-7632950-B2 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | QDPR, HRH4, HRH2 | MEN1 4011/4885KMT2A 2821/4885HRH4 2/4885 |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | QDPR, HRH4, HRH2 | MEN1 4011/4885KMT2A 2707/4885HRH4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.